Last Posted: May 14, 2020
- Development and validation of a five-immune gene prognostic risk model in colon cancer.
Chen Haitao et al. BMC cancer 2020 May 20(1) 395 - Immune-related adverse events of checkpoint inhibitors
MR Casals et al, Nature Rev did Primers - Radiomics and deep learning in lung cancer.
Avanzo Michele et al. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2020 May - Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?
RB Corcoran et al, JAMA Oncology, May 7, 2020 - Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu Hui et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 14(1) 25-36 - Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.
Pallocca Matteo et al. Journal of translational medicine 2019 17(1) 131 - What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
Bravaccini Sara et al. Lung cancer (Amsterdam, Netherlands) 2019 132152-153 - Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Yuankai et al. EBioMedicine 2020 Apr 54102731 - Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer
Y Yu et al, JAMA Network Open, April 7, 2020 - Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Goldberg Sarah B et al. The Lancet. Oncology 2020 Apr
.png)
No hay comentarios:
Publicar un comentario